MLP SE

  • WKN: 656990
  • ISIN: DE0006569908
  • Land: Deutschland

Nachricht vom 22.02.2021 | 16:54

MLP SE: Release of a capital market information

MLP SE / MLP SE / Disclosure according to Art. 5 para. 1(b), para 3 of Regulation (EU) No. 596/2014 in connection with Art. 2 para. 2 and 3 of Delegated Regulation (EU) 2016/1052 Share buyback - 7th Interim Reporting
22.02.2021 / 16:54
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

MLP SE / Share buyback

In the time period from February 15, 2021 until and including February 19, 2021, a number of 64,739 shares were bought back within the framework of the share buyback of MLP SE. The beginning of the share buyback on January 4, 2021 was disclosed on December 17, 2020 pursuant to Art. 5 (1) Regulation (EU) No 596/201 and Art. 2 (1) of Commission Delegation Regulation (EU) No 2016/1052.

Day of purchase Aggregated volumen in shares Average price (EUR)
15.02.2021 12,919 6.2904
16.02.2021 9,256 6.2597
17.02.2021 13,823 6.2370
18.02.2021 14,083 6.2268
19.02.2021 14,658 6.2506
 

The transactions are published in a detailed form on the website of MLP SE.
(www.mlp-se.com)

The total volume of shares which have been bought back within the framework of the share buyback in the time period of January 4, 2021 until and including February 19, 2021 amounts to 294,739 shares.

The purchase of the shares of MLP SE is carried out exclusively via the stock exchange (Xetra) by a bank commissioned by MLP SE.



22.02.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021